ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The emerging role of plasma lipidomics in cardiovascular drug discovery

Puri, Rishi; MyNgan Duong; Uno, Kiyoko; Kataoka, Yu; Nicholls, Stephen J.*
Expert Opinion on Drug Discovery2012-1DOI: 10.1517/17460441.2012.644041
19被引1阅读
引用收藏
分享

摘要

Introduction: With the rising global incidence of cardiovascular disease, the challenge for the pharmaceutical industry is to identify novel biomarkers that will allow not only for the development of the next generation of cardiometabolic therapeutics, but also to serve as a sensitive mechanism to monitor and predict drug efficacy and potential toxicity. The advent of an 'omics' (systems biological) approach has vast implications for future disease treatment and prevention. Lipidomics is the latest addition to the 'omics' family and is rapidly gaining attention due to the technological improvements in mass spectrometry, allowing for the characterization of large number of lipids (and their respective subclasses) in a short amount of time with relatively minimal preparation. Areas covered: The authors discuss the various techniques involved in plasma lipidomics as well as outline the role that lipidomics will play in phenotyping disease processes and corresponding therapeutic strategies. The article was formed through comprehensive Medline search of relevant publications in this area. Expert opinion: Despite the wealth of data that will emerge regarding the various lipid-molecular interactions and the functions of lipids within cells, a major challenge will be the parallel emergence of novel bioinformatics platforms in order to integrate this enormous data set with information generated from the emerging fields of genomics and proteomic analysis. Despite these challenges, lipidomics is likely to result in the reclassification of diseases from a molecular perspective and play a key role the eventuation of personalized medicine.

学科与关键词

关键词
cardiovasculardrug developmentdrug discoverylipidomics
相关
加载中…
  • Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future
    Rankin, Naomi J.*; Preiss, David; Welsh, Paul; Sattar, NaveedInternational Journal of Epidemiology, 2016, 45(5): 1351-1371.被引 18
  • Metabolomics applications in coronary artery disease personalized medicine
    Amin, Arwa M.*ELSEVIER ACADEMIC PRESS INC,525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA, 2021.被引 10
  • Insights into the prognosis of lipidomic dysregulation for death risk in patients with coronary artery disease
    Qin, Min; Zhu, Qian; Lai, Weihua; Ma, Qilin; Liu, Chen; Chen, Xiaoping; Zhang, Yuelin; Wang, Zixian; Chen, Hui; Yan, Hong; Lei, Heping; Zhang, Shuyao; Dong, Xuekui; Wang, Hong; Huang, Min; Lian, Qizhou; Zhong, Shilong*Clinical and Translational Medicine, 2020, 10(5): e189.被引 15
查看全部 →

发表信息

论文状态
公开发表
期刊
Expert Opinion on Drug Discovery
发表日期
2012-01
卷期
第 7 卷, 第 1 期
页码
63-72
DOI
10.1517/17460441.2012.644041
语言
ENGLISH
成果收录
SCIE
资助标注
National Health & Medical Research Council [565579]; National Heart Foundation of Australia [PC0804045]; Dawes Scholarships (Hanson Institute); AstraZeneca; Novartis; Resver-logix; Eli Lilly Co.; Anthera

作者

  • P

    Puri, Rishi (第一作者)

  • M

    MyNgan Duong

查看全部 5 位作者收起作者
  • U

    Uno, Kiyoko

  • K

    Kataoka, Yu

  • N

    Nicholls, Stephen J. (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417